TPO and autoimmune thrombocytopenic purpura: Cuker et al. expanded the definition of refractory ITP to include patients who need treatment but are unable or unwilling to have a splenectomy [111], while a complete lack of response to one or more single-agent treatments, such as rituximab and TPO-RA, was the definition of refractory ITP in 2020 [20].